Key result
IV verapamil cuts sustained circus movement tachycardia induction by ~75% versus baseline in WPW syndrome.
Why the study?
The electrophysiological effects of verapamil on accessory pathway properties and its role in preventing sustained circus movement tachycardia in Wolff-Parkinson-White syndrome were unclear.
Does intravenous verapamil alter accessory pathway properties and prevent circus movement tachycardia in patients with Wolff-Parkinson-White syndrome?
Population
10 patients with concealed or manifest Wolff-Parkinson-White syndrome
Comparison
Verapamil 0.2 mg/kg intravenously vs baseline
Design
Intracardiac recordings and electrical stimulation case series
Authors
Loading...
May support acute testing in WPW; leaves open randomized confirmation of clinical benefit.
Does intravenous verapamil alter accessory pathway properties and prevent circus movement tachycardia in patients with Wolff-Parkinson-White syndrome?
Absolute Event Rate: 20% vs 80%
Intravenous verapamil prevents sustained circus movement tachycardia in WPW syndrome by increasing AV nodal refractoriness without affecting accessory pathway properties.
Matsuyama et al. (1981) studied Wolff-Parkinson-White syndrome (n=10). Verapamil vs. Baseline (before administration) was evaluated on Induction of sustained circus movement tachycardia. Intravenous verapamil reduced the induction of sustained circus movement tachycardia from 80% at baseline to 20% in patients with Wolff-Parkinson-White syndrome.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: